Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.
Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed from the page.SummaryDifference0.1%
- Check29 days agoChange DetectedRemoved the general government funding/operating status notice from the page; no study details or trial data appear to be affected.SummaryDifference0.4%
- Check43 days agoChange DetectedThe new design reorganizes sections and adjusts visuals while core study details (title, conditions, interventions, eligibility criteria, primary/secondary outcomes, and enrollment) remain the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check72 days agoChange DetectedUpgrade to v3.2.0 with a government-operating-status notice; the previous v3.1.0 reference has been removed.SummaryDifference3%
- Check79 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%
- Check93 days agoChange DetectedPage now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' navigation element was removed.SummaryDifference0.2%
Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.